Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Morgan Caulfield

Physician Assistant Vicksburg, MS Physician Assistant

NPI 1174087209 CMS profile 10901483

2080 S Frontage Rd Ste 100, Vicksburg, MS 39180

Open in the dashboard

General payments

$2,110

115 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Morgan Caulfield of Vicksburg, MS is reported in the CMS Open Payments database as having received $2,110 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $682 38
2024 General $712 36
2023 General $375 20
2022 General $199 13
2021 General $141 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Morgan Caulfield
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Morgan Caulfield were reported at $682. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Morgan Caulfield Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $141 $132 $37–$438 $132
2022 $199 $155 $48–$522 $149
2023 $375 $167 $52–$557 $160
2024 $712 $178 $55–$600 $164
2025 $682 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $660 45 payments
  2. AstraZeneca Pharmaceuticals LP $354 19 payments
  3. Inari Medical, Inc. $226 3 payments
  4. Mylan Specialty L.P. $124 6 payments
  5. Astellas Pharma US Inc $102 4 payments
  6. Novartis Pharmaceuticals Corporation $84 5 payments
  7. Otsuka America Pharmaceutical, Inc. $79 5 payments
  8. GlaxoSmithKline, LLC. $66 4 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $57 3 payments
  10. Abbott Laboratories $51 3 payments
  11. Other $306 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,098 114 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. DALVANCE $357 24 payments
  2. BREZTRI $296 15 payments
  3. CT THROMBECTOMY SYSTEM KIT $226 3 payments
  4. FLOWTRIEVER CATHETER, S $226 3 payments
  5. TEFLARO $181 12 payments
  6. AVYCAZ $167 11 payments
  7. YUPELRI $124 6 payments
  8. VRAYLAR Neuroscience $116 8 payments
  9. Veozah $102 4 payments
  10. VRAYLAR Neuroscience $87 6 payments
  11. Other $1,010 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 153 drugs

Part D claims

9,178

Median for Physician Assistant: 241

Drug cost

$668,481

Median for Physician Assistant: $4,110

Branded share of claims

23.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 65 $88,824
Eliquis Apixaban Brand 103 $69,639
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 76 $60,902
Jardiance Empagliflozin Brand 66 $56,289
Linzess Linaclotide Brand 65 $45,196
Xarelto Rivaroxaban Brand 66 $42,356
Trulicity Dulaglutide Brand 16 $37,891
Mounjaro Tirzepatide Brand 30 $31,667
Brilinta Ticagrelor Brand 27 $16,039
Januvia Sitagliptin Phosphate Brand 13 $15,622

The 10 drugs with the highest cost, of 153 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$188,223

Of which drugs: $8,376

Medicare patients

444

Average age 75

Services billed

8,782

259 women, 185 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Diabetes 39%
Ischemic heart disease 37%
COPD 30%
Heart failure 24%
Depression 24%
Atrial fibrillation 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 35 35 $2,818
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 1,320 $124
Injection, ketorolac tromethamine, per 15 mg J1885 Office 42 173 $82
Injection, methylprednisolone acetate, 80 mg J1040 Office 13 14 $54
Injection, ceftriaxone sodium, per 250 mg J0696 Office 26 112 $35
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 86 390 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $98
$98 11 —
DALVANCE
  • AbbVie, Inc. $71
$71 — —
TEFLARO
  • AbbVie, Inc. $45
$45 — —
AVYCAZ
  • AbbVie, Inc. $31
$31 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record